Quad recall
Executive Summary
Firm announced March 22 that it will recall 22 generic injectable products, following a March 21 meeting with FDA. The agency told "The Pink Sheet" that at the meeting, the company agreed to a 38-product recall. The impending Class III recall relates to unapproved manufacturing changes for some of the firm's drugs. Quad said it may reintroduce some of these products by manufacturing them according to the original terms of the ANDAs. The company estimates the cost of the recall at about $4 mil. Last week, the Par subsidiary suspended distribution of 27 products as a result of internal and external audits that discovered manufacturing changes made without proper FDA authorization. Quad has not yet agreed with FDA's suggestion that the firm recall the drugs down to the retail level, the agency noted. In a related move, the company announced plans to lay off almost 30% of its 380-employee workforce.
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.